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Adenovirus type 5 (Ad5) E3 region proteins abrogate Ad pathogenicity in the lungs of cotton rats. Our use of Ad4-HIV
E3-deleted (DE3) recombinants as vaccines necessitates further examination of these viruses for enhanced pathogenesis.
Equivalent infectious doses of Ad4 wild-type (Ad4WT), Ad4DE3, and two recombinants: Ad4DE3HIVenv and Ad4DE3HIVgag,
were inoculated intranasally into cotton rats. Ad4 viruses did not replicate in the lungs, but caused mild pathologic effects,
including peribronchiolitis, bronchitis, alveolitis, and interstitial pneumonia. As found previously for Ad5, deletion of Ad4 E3
genes resulted in increased lung pathology. Surprisingly, insertion of HIV genes into this region significantly restored
protection attributed to E3 gene products, diminishing overall pathologic effects to Ad4WT levels (P , 0.0001). Similarly,
following administration of equivalent particle numbers of the four viruses, only Ad4DE3 caused increased overall pathology,
while the two HIV recombinant viruses showed effects comparable to Ad4WT (P , 0.01). Our observation that Ad4DE3HIV
recombinants are as safe in cotton rats as Ad4WT encourages their continued development as AIDS vaccines. © 2002 Elsevier
Science
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The cotton rat, Sigmodon hispidus, has been used as
a model to assess the molecular determinants of ade-
novirus (Ad)-induced lung pathology (Ginsberg and
Prince, 1994; Ginsberg et al., 1989). Ginsberg et al. (1989)
determined that both Ad5 and Ad2 replicate in the lungs
of cotton rats and elucidated the importance of the E3
gene in pathogenesis. Mutants lacking functional gene
products encoded by E3 were shown to replicate, but
exhibited a greater degree of lung pathology. This was
attributed to the role of these proteins in reducing ex-
pression of MHC class I antigens on cell surfaces, pro-
tecting cells from tumor necrosis factor (TNF) cytolysis,
and modulating host cytokines. Lungs of rats infected
with E3-deleted viruses displayed a greater inflammatory
response involving early infiltration of lymphocytes and
monocyte/macrophages well before the time when Ad-
specific cytotoxic T lymphocytes (CTLs) would appear.
Overall, the function of the E3-encoded proteins in re-
ducing viral pathology could be an advantage for the
virus, protecting it from Ad-specific CTL and innate im-
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Library Drive MSC 5055, Building 41, Room D804, Bethesda, Maryland
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107mune responses, thereby helping to establish persis-
tence (Wold and Gooding, 1991).
The increased lung pathology of cotton rats exposed
intranasally to the Ad5DE3 vector has called into ques-
tion the safety of Ad recombinants based in E3-deleted
vectors (Ginsberg et al., 1989). We are pursuing an Ad-
recombinant priming/subunit boosting approach for
AIDS vaccine development using E3-deleted, replication
competent Ad-HIV recombinants. Our results in chim-
panzees have suggested that animals that replicate the
recombinant virus to the highest levels and for the long-
est period of time develop the strongest HIV-specific
immune responses and exhibit the greatest protection
from HIV challenge (Lubeck et al., 1997; Robert-Guroff et
al., 1998). The early successes of this approach have
provided the basis for moving our Ad4DE3HIV recombi-
nants into phase I human trials, making safety of these
vaccine materials a critical issue. Wild-type (WT) Ad4
and Ad7 have been safely administered orally to people
at doses of 105 and 107 TCID50, respectively (Takafuji et
al., 1979), and Ad4 has been safely administered intra-
nasally to Ad-seropositive and Ad-seronegative volun-
teers at doses of 105 and 104 PFU, respectively (Smith et
al., 1970). To determine whether Ad4DE3HIV recombi-
nants might be more pathogenic than Ad4WT, we asked
three questions. First, does Ad4WT replicate in the lungs
of cotton rats? Second, does deletion of the E3 gene
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108 PATTERSON ET AL.cause markedly increased pathology of the Ad4 vector in
the cotton rat model? Third, what effect does insertion of
HIV-1 env and/or gag-pro genes into the Ad4DE3 vector
have on pathology?
RESULTS
Determination of Ad4-induced pathology
Initially we asked if Ad4WT would replicate in cotton
rats and cause lung pathology. Twelve cotton rats were
each infected intranasally with 107 PFU of Ad4WT in 100
ml PBS. Each subsequent day, three animals were sac-
rificed for histology and analysis of virus replication in
the lungs. Ad4WT did not replicate in the cotton rat. Ad
titers in lung homogenates were routinely negative, or
occasionally 101 PFU/ml. Lung homogenates of rats ad-
ministered Ad4DE3 or Ad4DE3HIV recombinants in the
experiments below also failed to replicate (data not
shown).
Although not replicating, Ad4WT induced lung pathol-
ogy. The kinetics of appearance of pathologic effects,
scored for peribronchiolitis, bronchitis, alveolitis, and in-
terstitial pneumonia, are shown in Table 1. Pathologic
effects were modest, but most extensive, on day 3.
Effect of viral dose on pathogenicity
To establish a dose for maximal pathogenic effect, 106,
107, or 108 PFU of both Ad4WT and Ad4DE3 viruses were
T
Kinetics of Adenovirus Type 4-In
Virus
No. of
rats
Day of
sacrifice
Viral dose
(PFU) P
Ad4WT 3 1 107
3 2 107
3 3 107
3 4 107
Note. Lung pathology was scored on a scale of 0 to 4 as described
T
Effect of Ad4WT and Ad4DE3
Virus
No. of
rats
Day of
sacrifice
Viral dose
(PFU) P
Ad4WT 3 3 108
3 3 107
3 3 106
Ad4DE3 2 3 108
3 3 107
3 3 106
a Score for one rat only. One of two rats tested died before the day 3
inoculum at the onset of the experiment, the total volume was insufficient. Th
administration of both Ad4WT and Ad4DE3 viruses was at or approaching madministered as before to six groups of cotton rats, three
animals/group. Animals given 108 PFU of Ad4WT devel-
oped extensive lung pathology. At lesser doses, the ef-
fects were minimal (Table 2). Pathologic effects of
Ad4DE3 were more severe than those induced by
Ad4WT. One of two rats given 108 PFU of Ad4DE3 died
before lungs could be harvested (Table 2).
Comparative pathogenicity of Ad4WT, Ad4DE3, and
Ad4DE3HIV recombinants
Four groups of 10 rats each were used to compare
pathogenic effects among the Ad4 viruses at an infec-
tious dose of 5 3 107 PFU/rat. Lungs were harvested on
day 3 (Table 3). The Ad4DE3-inoculated animals scored
highest for the overall measure (sum) of pathogenicity
(P , 0.0001) compared to the other three groups. This
was due primarily to marked differences in alveolitis and
interstitial pneumonitis scores (P , 0.0001). Surpris-
ingly, both groups of rats that received Ad4DE3HIV re-
combinants containing either env or gag-pro showed a
nullification of overall lung pathology; pathologic effects
were even less compared to Ad4WT infection in overall
pathology score (P , 0.05) (Table 3). Less striking
differences in extent of peribronchiolitis were observed
among the groups, and no differences in bronchitis were
seen (Table 3). Pathologic effects in representative lung
sections of rats infected with Ad4WT, Ad4DE3, and
Ad4DE3HIVgag are illustrated in Fig. 1. The increased
Lung Pathology in Cotton Rats
chiolitis Bronchitis Alveolitis
Interstitial
pneumonitis
1 0.3 0 0
1.7 0.3 0.7 0.7
2 1.3 1.7 0.7
1.3 1.3 0.3 0
Materials and Methods. Mean scores within each category are listed.
ous Dose on Lung Pathology
chiolitis Bronchitis Alveolitis
Interstitial
pneumonitis
2 1.3 3.3 3.3
1 0 0 0
0.3 0 0 0
2a 1a 4a 4a
1.7 1 1 1
1.3 0.3 0 0
t of lung tissue. A third rat was not inoculated. Upon thawing the viral
8ABLE 1
duced
eribronABLE 2
Infecti
eribron
harves
e 10 PFU dose was not repeated, as lung pathology in response to
aximal pathologic effect.
less tha
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Ad4DE3HIVgag is readily apparent. Pathogenic effects of
Ad4DE3HIVenv were similar to those induced by
Ad4DE3HIVgag (not shown).
The particle/plaque forming unit (p/PFU) ratios for the
different viral preparations were not uniform (see Mate-
rials and Methods). Both Ad4DE3 and Ad4WT viral prep-
arations had a greater number of noninfectious particles
than either Ad4DE3HIVenv or Ad4DE3HIVgag. We there-
fore performed a separate experiment to determine
whether pathologic effects were dependent on total viral
particle number. After dosing based on equivalent parti-
cle number, Ad4DE3-immunized cotton rats continued to
exhibit significantly higher mean scores (sum of 3.5) for
lung pathology than to the other three groups (P ,
0.01), confirming the results seen based on PFU (Table
4). Again, the Ad4DE3HIV recombinants did not elicit an
increased pathologic effect.
DISCUSSION
Initially undertaken to assess the safety of Ad4DE3HIV
recombinants that will be utilized in human phase I
vaccine trials, this study has also shed light on the
complex nature of viral–host immune interactions. First,
we have clearly established that unlike Ad2 and Ad5,
neither Ad4WT, the E3-deleted vector, or the engineered
recombinants replicate in the lungs of cotton rats. Nev-
ertheless, these Ad4 viruses are able to infect cotton rat
cells and presumably express early genes, thereby mod-
ulating host immunity and inducing immune responses
resulting in lung pathology.
Second, we have shown that E3 deletion of Ad4, a
group E virus, results in modulation of the host immune
response, leading to increased pathology in lungs of
T
Histopathology Induced by Ad4WT, Ad4DE3, Ad4DE3
Virus
No. of
rats
Day of
sacrifice
Viral dose
(PFU) Peribron
Ad4WT 10 3 5 3 107 1.7
Ad4DE3 10 3 5 3 107 1.9
P ,
Ad4DE3HIVgag 10 3 5 3 107 0.9
P ,
Ad4DE3HIVenv 10 3 5 3 107 1.3
P ,
a Overall mean score is the sum of the four individual pathology sco
b Peribronchiolitis from Ad4DE3 greater than Ad4DE3HIVgag and Ad
c Peribronchiolitis from Ad4DE3HIVgag and Ad4DE3HIVenv less tha
d Overall pathology score, alveolitis, and interstitial pneumonitis fro
0.0001).
e Overall pathology score from Ad4DE3HIVgag and Ad4DE3HIVenvcotton rats as has been shown for group C Ad. The 19K
glycoprotein of Ad4 has been shown to bind MHC classI antigens (Paabo et al., 1986), suggesting a function
similar to that of the Ad2 and Ad5 19K glycoprotein. As
significant pathology occurred here within 3 days of
Ad4DE3 administration, it is also likely that the Ad4 E3
region genes similarly modulate the host cytokine re-
sponse, as effects of enhanced CTL induction would not
be expected to occur so rapidly.
Third and quite remarkably, insertion of HIV-1 env or
gag-pro into the Ad4DE3 vector restored the protective
effect lost by deletion of the E3 region, abrogating the
increased pathology and producing effects similar to or
less severe than those induced by Ad4WT. The mecha-
nism(s) responsible for this result is unknown. However,
viruses in general have evolved strategies to combat
host immune responses, and HIV is not unusual in this
regard. HIV gp120, the external envelope protein, is
known to be immune suppressive. It decreases PHA-
induced blastogenesis, blocks CD41 T cell activation,
down-regulates chemotactic ligand receptors, and inhib-
its IL2-mRNA expression (Peruzzi et al., 2000). Recently,
gp120 was shown to inhibit natural killer (NK) cell cyto-
toxicity and interferon-g production (Peruzzi et al., 2000),
both mediators of innate immunity, most important early
in the infection process. The HIV transmembrane protein,
gp41, also has immune suppressive activity, including
inhibition of NK activity (Cauda et al., 1988). It is thus
possible that the modulation of host cytokines by ex-
pressed HIV envelope counteracts the loss of viral pro-
tection provided by the E3 region gene products.
The basis for HIV gag-mediated alteration of Ad4DE3-
induced lung pathology is more difficult to explain, as the
gag gene products are not known as immune suppres-
sive. However, several observations suggest that ex-
pressed viral structural proteins may also modulate host
g, and Ad4DE3HIVenv, Adjusted for Infectious Dose
Bronchitis Alveolitis
Interstitial
pneumonitis
Overall
mean scorea
1.1 0.7 0.8 4.3
1.8 3.1d 3.2d 10.0d
P , 0.0001 P , 0.0001 P , 0.0001
0.9 0.2 0.2 2.2e
P , 0.05
1.0 0.1 0.2 2.6e
P , 0.05
each category.
IVenv (P , 0.05).
T (P , 0.05).
DE3 greater than Ad4DE3HIVgag, Ad4DE3HIVenv, and Ad4WT (P ,
n Ad4WT (P , 0.05).ABLE 3
HIVga
chiolitis
b
0.05
c
0.05
c
0.05
res in
4DE3H
n Ad4W
m Ad4cytokines. The HIV gag p17 protein has been reported to
inhibit T cell proliferation (Hofmann et al., 1994). The p24
FIG. 1. Histopathology of cotton rat lungs 3 days following administration of adenoviruses. Sections shown are representative of those within each
experimental group. (A) Infected with Ad4WT. Mild peribronchiolitis, bronchitis, and alveolitis: no interstitial pneumonitis evident. (B) Infected with
Ad4DE3. Peribronchiolitis is equivalent to that seen in (A), and bronchitis is slightly more intense. By contrast, there is marked alveolitis and interstitial
pneumonitis throughout the section. (C) Infected with Ad4DE3HIVgag. Mild peribronchiolitis and bronchitis, slightly reduced in comparison to (A); no
alveolitis or interstitial pneumonitis evident. H&E staining, magnification, 3100.
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111DECREASED PATHOGENICITY OF Ad4DE3HIV RECOMBINANTScore protein can inhibit the interferon-g-induced in-
crease of HLA-DR mRNA in the THP-1 monocyte cell line,
suggesting that it may affect the ability of macrophages
to be appropriately activated in vivo (Nong et al., 1991).
p24 has also been reported to contribute to myelopoietic
suppression as a result of soluble factors induced by the
interaction of p24 with bone marrow stroma (Rameshwar
et al., 1996). While this may not be relevant to the lung
pathology observed here, it suggests the potential for
p24-induced modulation of host immunity by perhaps as
yet unidentified factors. Thus the encoded proteins of
both HIV env and HIV gag-pro have the potential to
replace the viral protective effects provided by the Ad E3
region gene products.
FIG. 1
T
Histopathology Induced by Ad4WT, Ad4DE3, Ad4DE
Virus
No. of
rats
Day of
sacrifice
Viral dose
(particles) Peribro
Ad4WT 7 3 6.6 3 107
Ad4DE3 7 3 6.6 3 107
Ad4DE3HIVgag 7 3 6.6 3 107
Ad4DE3HIVenv 7 3 6.6 3 107a Overall pathology score from Ad4DE3 greater than Ad4WT, Ad4DE3HIVenThe fact that our four viral preparations exhibited
p/PFU ratios ranging from 1:1 for Ad4DE3HIVenv to 20:1
for Ad4DE3 suggested that absolute differences in num-
ber of viral particles administered, even though defec-
tive, might have influenced the pathologic outcomes.
Such a result would have been unexpected, based on
earlier results showing that when Ad5WT is first UV
irradiated before inoculating into cotton rats, thereby
inactivating infectivity, pulmonary inflammation is ablated
(G. Prince, unpublished results). Nevertheless, we ad-
dressed this question by performing an experiment in
which cotton rats were dosed with equivalent numbers
of particles of each viral preparation. We again showed
that the HIV-recombinant viruses did not elicit any
inued
g, and Ad4DE3HIVenv, Adjusted for Particle Count
itis Bronchitis Alveolitis
Interstitial
pneumonitis
Overall
mean score
0.2 0 0 1
0.9 0.6 0.3 3.5a
0.4 0 0 1.3
0.1 0.4 0.1 1.5ABLE 4
3HIVga
nchiol
0.8
1.7
0.9
0.9v, and Ad4DE3HIVgag (P , 0.01).
112 PATTERSON ET AL.greater pathologic effect than Ad4WT (Table 4). This
result lends further confirmation that adenovirus-specific
cell entry in the lungs as opposed to purely antigen load
is required for induction of pathology. This explains the
lessened overall pathology observed when cotton rats
were administered equivalent total particle numbers,
with a corresponding lower infectious titer for each stock
(Table 4), compared to when they were dosed with equiv-
alent infectious particles (5 3 107 PFU, Table 3). As
expected, viruses with p/PFU ratios of 1:1 and 4:1
(Ad4DE3HIVenv and Ad4DE3HIVgag, respectively) exhib-
ited less of a difference in overall pathology between
experiments compared to Ad4WT and Ad4DE3, which
had p/PFU ratios of 10:1 and 20:1, respectively.
Further experiments will be required to elucidate the
mechanism of the Ad-HIV recombinant effect and to
establish whether HIV env and gag-pro genes inserted
into an Ad5DE3 vector able to replicate in cotton rats will
also abrogate increased pathogenicity. For purposes of
HIV vaccine design, it will also be important to determine
the extent to which other HIV gene products exert similar
effects. Nevertheless, these observations showing that
Ad4DE3HIV recombinants are no more pathogenic than
Ad4WT virus bode well for the continued use of a repli-
cation-competent Ad-vectored approach for AIDS vac-
cine development. Our results suggest that deletion of
E3 region genes should not be a safety issue related
to intranasal administration of Ad4DE3HIVenv or
Ad4DE3HIVgag to people.
MATERIALS AND METHODS
Viruses
An Ad4 vector deleted in the E3 region between map
units 76 and 86 (Ad4DE3) was used in constructing
recombinant viruses containing either the HIV-1MNenv
and rev genes (Ad4DE3tplMNenvtplHrev, abbreviated
here as Ad4DE3HIVenv) or the HIV-1LAV gag-pro and
rev genes (Ad4DE3tplgagHrev, abbreviated here as
Ad4DE3HIVgag) as previously described (Chanda et al.,
1990; Vernon et al., 1991). Viruses, including Ad4WT,
were amplified on QBI 293 cells at an m.o.i. of 0.1, purified
over two CsCl gradients, and titered on 293 cells. The
p/PFU ratios for each stock were determined. For
Ad4DE3HIVenv, the particle count and infectious titer
were equivalent with a p/PFU ratio of 1:1. For other
stocks, the p/PFU ratios ranged from 4:1 for Ad4DE3HIVgag
to 10:1 and 20:1 for Ad4WT and Ad4DE3, respectively.
Animals
Inbred cotton rats, negative for antibodies to
paramyxoviruses, respiratory syncytial virus, and rodent
viruses, were obtained from a colony maintained at
Virion Systems, Inc., Rockville, MD. The animals were, on
average, 5 weeks old and weighed 60 g at the time they
were used.Experimental design
Cotton rats were anesthetized with methoxyflurane
and inoculated intranasally with 100 ml of virus suspen-
sion of the type and at the dose indicated. They were
sacrificed on indicated days by carbon dioxide inhala-
tion. Lungs were bisected, with one-half being homoge-
nized for viral titration and the other half being inflated
intratracheally with 10% neutral buffered formalin for his-
tologic study. Paraffin-embedded tissues were sectioned
at a thickness of 4 mm and stained with hematoxylin and
eosin (H&E).
Histologic analysis
Four parameters of pulmonary inflammatory changes
were scored in each lung section: peribronchiolitis (in-
flammatory cells, primarily lymphocytes, surrounding a
bronchiole); bronchitis (neutrophils within the bronchial
epithelium); alveolitis (inflammatory cells within alveolar
spaces); and interstitial pneumonitis (increased thick-
ness of alveolar walls associated with inflammatory
cells). Prior to scoring, the slides were randomized and
then read blindly. Each parameter was scored separately
for each histologic section, on a semiquantitative scale
ranging from 0 (no inflammation) to 4 (maximum inflam-
mation). Although each was scored using the same
scale, the scores are relative and valid only for compar-
ing the same parameter in different sections and not for
comparing different parameters within a section.
Titration of virus in lung homogenates
A549 cells (ATCC, Rockville, MD) were seeded into
60-mm tissue culture dishes (Nunc) at 1.5 3 106 cells in
5 ml Hams F12K media (Gibco-BRL) supplemented with
10% FBS, 1% L-glutamine, and pen-strep (Gibco-BRL). The
resultant monolayers reached 90–100% confluency the
next day. After aspirating the media, 500 ml of diluent
consisting of Hams F12K media without serum was
added to each dish. Lung homogenates (100 ml undi-
luted, or 1021 and 1022 dilutions) were added to duplicate
dishes and incubated for 1 h at 37°C, with rocking every
15 min. The inoculum was removed and the cell mono-
layer was washed once with diluent and then overlayed
with 4 ml of media containing Hams F12K, 2% FBS, and
0.5% ultrapure agarose (Gibco-BRL). Plates were incu-
bated for 6 days, with feeding on day 3 with 2 ml of
overlay medium. On the sixth day, 2 ml of overlay medium
containing 3% neutral red (Gibco-BRL) was added to
each plate and plaques were counted the next day.
Statistical analysis
Multivariate analysis of variance (MANOVA) was used
to determine global group differences on the four patho-
genicity parameters described. Univariate analyses of
variance (ANOVA) and standard post hoc tests were
113DECREASED PATHOGENICITY OF Ad4DE3HIV RECOMBINANTSused in follow-up analyses on individual parameters as
well as on their sums.
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